.Nature Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused enhanced progression-free and overall survival, triggering FDA commendation and a brand-new therapy option for individuals.